Confronto
Leuprorelin vs. Pasireotid
Due peptidi a confronto — identità, base di evidenze, stato legale ed eventi avversi noti.
Identità
Categoria
Ricerca (altro)
Ricerca (altro)
N. CAS
53714-56-0
396091-73-9
Peso molecolare
1209.4 g/mol
1047.21 g/mol
Emivita
3 h
nessun dato
Sequenza
Pyr-His-Trp-Ser-Tyr-D-Leu-Leu-Arg-Pro-NHEtnessun dato
Meccanismo d'azione
Leuprorelin
Leuprorelin is a GnRH-receptor agonist. After binding to pituitary GnRH receptors, it first causes a transient surge in luteinizing hormone (LH) and follicle-stimulating hormone (FSH) release — the so-called flare. With continuous, non-pulsatile exposure the receptors are downregulated and desensitized, suppressing gonadotropin secretion and consequently lowering sex steroids (testosterone or estradiol) to low levels. This mechanism underlies the literature-described use in hormone-dependent conditions.
Pasireotid
Pasireotide binds more broadly than older somatostatin analogs (SSTR1/2/3/5) with particularly high affinity for SSTR5. This suppresses, among others, ACTH release in Cushing's disease and GH release in acromegaly.
Base di evidenze
Evidenza più alta
RCT sull'uomo
RCT sull'uomo
Studi
4
1
di cui sull'uomo
4
1
Effetti registrati
4
2
Contraddizioni aperte
1
0
Eventi avversi documentati
3
2
Stato legale
Voci complete
Frequently asked questions
- What is the difference between Leuprorelin and Pasireotid?
- Leuprorelin is classified as "Ricerca (altro)", while Pasireotid is classified as "Ricerca (altro)". Leuprorelin: Leuprorelin (also leuprolide) is a synthetic nonapeptide analogue of gonadotropin-releasing hormone (GnRH/LHRH). It is an approved prescription medicine in several jurisdictions, including for advanced prostate cancer, endometriosis, uterine fibroids and central precocious puberty. This page neutrally summarizes the evidence base and legal status and is not a usage or dosing recommendation. Pasireotid: Pasireotide is a multireceptor somatostatin analog binding to four of the five somatostatin receptors (especially SSTR5). It is approved for Cushing's disease and acromegaly. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, Leuprorelin or Pasireotid?
- The highest available evidence level is "RCT sull'uomo" for Leuprorelin and "RCT sull'uomo" for Pasireotid. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of Leuprorelin and Pasireotid in Germany and the United States?
- Germania: Leuprorelin — Su prescrizione, Pasireotid — Su prescrizione. Stati Uniti: Leuprorelin — Su prescrizione, Pasireotid — Su prescrizione. These are factual summaries with source and review date on the individual pages.